Sign In
Buy SRDX
$42.98
+0 (+0%)
At Close: Feb 24, 2026
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
09:20am, Thursday, 30'th Jan 2025
SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
08:26am, Thursday, 23'rd Jan 2025
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
10:36am, Tuesday, 14'th Jan 2025
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:16pm, Friday, 03'rd Jan 2025
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for January 3rd
11:10am, Friday, 03'rd Jan 2025
SRDX and CWAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
New Strong Buy Stocks for January 3rd
06:26am, Friday, 03'rd Jan 2025
UAA, BRBR, RBA, SRDX and CTRA have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
06:48am, Monday, 09'th Dec 2024
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
01:50pm, Tuesday, 12'th Nov 2024
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
11:10am, Thursday, 07'th Nov 2024
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
09:21am, Wednesday, 06'th Nov 2024
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
02:30pm, Wednesday, 30'th Oct 2024
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early
SRDX Stock Down Despite FDA Clearance for Pounce XL System
11:35am, Wednesday, 02'nd Oct 2024
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Friday, 06'th Sep 2024
SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
10:35am, Thursday, 05'th Sep 2024
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 15'th Aug 2024
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
